Junchao Shen1, Noor Amari1, Rebecca Zack1, R Tyler Skrinak1, Travis L Unger1, Marijan Posavi1, Thomas F Tropea1, Sharon X Xie2, Vivianna M Van Deerlin3, Richard B Dewey4, Daniel Weintraub5,6, John Q Trojanowski3, Alice S Chen-Plotkin1. 1. Departments of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 2. Departments of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 3. Departments of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 4. Department of Neurology, University of Texas Southwestern Medical Center, Dallas, TX. 5. Departments of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 6. Parkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veterans Affairs Medical Center, Philadelphia, PA.
Abstract
OBJECTIVE: Using a multi-cohort, discovery-replication-validation design, we sought new plasma biomarkers that predict which individuals with Parkinson's disease (PD) will experience cognitive decline. METHODS: In 108 discovery cohort PD individuals and 83 replication cohort PD individuals, we measured 940 plasma proteins on an aptamer-based platform. Using proteins associated with subsequent cognitive decline in both cohorts, we trained a logistic regression model to predict which patients with PD showed fast (> = 1 point drop/year on Montreal Cognitive Assessment [MoCA]) versus slow (< 1 point drop/year on MoCA) cognitive decline in the discovery cohort, testing it in the replication cohort. We developed alternate assays for the top 3 proteins and confirmed their ability to predict cognitive decline - defined by change in MoCA or development of incident mild cognitive impairment (MCI) or dementia - in a validation cohort of 118 individuals with PD. We investigated the top plasma biomarker for causal influence by Mendelian randomization (MR). RESULTS: A model with only 3 proteins (melanoma inhibitory activity protein [MIA], C-reactive protein [CRP], and albumin) separated fast versus slow cognitive decline subgroups with an area under the curve (AUC) of 0.80 in the validation cohort. The individuals with PD in the validation cohort in the top quartile of risk for cognitive decline based on this model were 4.4 times more likely to develop incident MCI or dementia than those in the lowest quartile. Genotypes at MIA single nucleotide polymorphism (SNP) rs2233154 associated with MIA levels and cognitive decline, providing evidence for MIA's causal influence. CONCLUSIONS: An easily obtained plasma-based predictor identifies individuals with PD at risk for cognitive decline. MIA may participate causally in development of cognitive decline. ANN NEUROL 2022;92:255-269.
OBJECTIVE: Using a multi-cohort, discovery-replication-validation design, we sought new plasma biomarkers that predict which individuals with Parkinson's disease (PD) will experience cognitive decline. METHODS: In 108 discovery cohort PD individuals and 83 replication cohort PD individuals, we measured 940 plasma proteins on an aptamer-based platform. Using proteins associated with subsequent cognitive decline in both cohorts, we trained a logistic regression model to predict which patients with PD showed fast (> = 1 point drop/year on Montreal Cognitive Assessment [MoCA]) versus slow (< 1 point drop/year on MoCA) cognitive decline in the discovery cohort, testing it in the replication cohort. We developed alternate assays for the top 3 proteins and confirmed their ability to predict cognitive decline - defined by change in MoCA or development of incident mild cognitive impairment (MCI) or dementia - in a validation cohort of 118 individuals with PD. We investigated the top plasma biomarker for causal influence by Mendelian randomization (MR). RESULTS: A model with only 3 proteins (melanoma inhibitory activity protein [MIA], C-reactive protein [CRP], and albumin) separated fast versus slow cognitive decline subgroups with an area under the curve (AUC) of 0.80 in the validation cohort. The individuals with PD in the validation cohort in the top quartile of risk for cognitive decline based on this model were 4.4 times more likely to develop incident MCI or dementia than those in the lowest quartile. Genotypes at MIA single nucleotide polymorphism (SNP) rs2233154 associated with MIA levels and cognitive decline, providing evidence for MIA's causal influence. CONCLUSIONS: An easily obtained plasma-based predictor identifies individuals with PD at risk for cognitive decline. MIA may participate causally in development of cognitive decline. ANN NEUROL 2022;92:255-269.
Authors: A Siderowf; S X Xie; H Hurtig; D Weintraub; J Duda; A Chen-Plotkin; L M Shaw; V Van Deerlin; J Q Trojanowski; C Clark Journal: Neurology Date: 2010-08-18 Impact factor: 9.910
Authors: Harriet M Kluger; Kathleen Hoyt; Antonella Bacchiocchi; Tina Mayer; Jonathan Kirsch; Yuval Kluger; Mario Sznol; Stephan Ariyan; Annette Molinaro; Ruth Halaban Journal: Clin Cancer Res Date: 2011-04-12 Impact factor: 12.531
Authors: Stefanie Lerche; Isabel Wurster; Benjamin Röben; Milan Zimmermann; Gerrit Machetanz; Sarah Wiethoff; Monique Dehnert; Lea Rietschel; Benjamin Riebenbauer; Christian Deuschle; Elke Stransky; Inga Lieplt-Scarfone; Thomas Gasser; Kathrin Brockmann Journal: Mov Disord Date: 2020-05-23 Impact factor: 10.338
Authors: Kara Pigott; Jacqueline Rick; Sharon X Xie; Howard Hurtig; Alice Chen-Plotkin; John E Duda; James F Morley; Lama M Chahine; Nabila Dahodwala; Rizwan S Akhtar; Andrew Siderowf; John Q Trojanowski; Daniel Weintraub Journal: Neurology Date: 2015-09-11 Impact factor: 9.910
Authors: Lu He; Eun-Young Lee; Nicholas W Sterling; Lan Kong; Mechelle M Lewis; Guangwei Du; Paul J Eslinger; Xuemei Huang Journal: J Parkinsons Dis Date: 2016-05-31 Impact factor: 5.568
Authors: Brit Mollenhauer; Mirko Bibl; Jens Wiltfang; Petra Steinacker; Barbara Ciesielczyk; Karin Neubert; Claudia Trenkwalder; Markus Otto Journal: Clin Chem Lab Med Date: 2006 Impact factor: 3.694
Authors: Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris Journal: Mov Disord Date: 2008-04-30 Impact factor: 10.338